Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer
Putora P, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M. SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. Oncol Res Treat 2016; 39:681-686.
Oct 19, 2016SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer
Oct 19, 2016Oncol Res Treat 2016; 39:681-686
Putora Paul Martin, Szentesi Kinga, Glatzer Markus, Rodriguez Regulo, Müller Joachim, Baty Florent, Früh Martin
Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. Nutrition 2016; 35:43-50.
Oct 15, 2016Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison
Oct 15, 2016Nutrition 2016; 35:43-50
Baumgartner Annic, Mueller Beat, Stanga Zeno, Hess Urs, Duchosal Michel A, Pabst Thomas, Wannesson Luciano, Limonta Alessandro, Pichard Claude, Chalandon Yves, Samaras Panagiotis, Schanz Urs, Passweg Jakob, Medinger Micheal, Zueger Noemi, Bargetzi Annika, Bargetzi Mario, Schuetz Philipp
GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography
Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. JAAD Case Rep 2016; 2:415-417.
Oct 13, 2016GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography
Oct 13, 2016JAAD Case Rep 2016; 2:415-417
Hasan Ali Omar, Diem Stefan, Aschwanden Josef, Markert Eva, Tasman Abel-Jan, Müller Joachim, Flatz Lukas
Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients
Siano M (2016). Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients.
Oct 11, 2016Presence of percutaneous endoscopic gastrostomy tube (PEG) is an independent negative prognostic factor in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) patients
Oct 11, 2016-
Siano Marco
Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting
Siano M (2016). Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting.
Oct 11, 2016Baseline neutrophil-to-lymphocyte ratio is associated with outcome in recurrent/metastatic head and neck squamous cell cancer patients treated with platinum and cetuximab in first line setting
Oct 11, 2016-
Siano Marco
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey
Lorente D, Hall E, IJzerman M, Terstappen L, Payne H, Mateo J, Perez R, Tunariu N, Bianchini D, Porta N, Kolinsky M, Rescigno P, Miranda M, Gilman A, Omlin A, Pezaro C, Mehra N, Ravi P, de Bono J. Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. Eur Urol Focus 2016; 4:235-244.
Oct 10, 2016Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey
Oct 10, 2016Eur Urol Focus 2016; 4:235-244
Lorente David, Hall Emma, IJzerman Maarten, Terstappen Leon, Payne Heather, Mateo Joaquin, Perez Raquel, Tunariu Nina, Bianchini Diletta, Porta Nuria, Kolinsky Michael, Rescigno Pasquale, Miranda Miguel, Gilman Alexa, Omlin Aurelius, Pezaro Carmel, Mehra Niven, Ravi Praful, de Bono Johann
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
Oct 10, 2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Oct 10, 2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese W, Kopit J, Shaw J, Gillison M. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375:1856-1867.
Oct 8, 2016Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Oct 8, 2016N Engl J Med 2016; 375:1856-1867
Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Geese William J, Kopit Justin, Shaw James W, Gillison Maura L
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L, Speiser D, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016; 5:e1231292.
Sep 19, 2016Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
Sep 19, 2016Oncoimmunology 2016; 5:e1231292
Hasan Ali Omar, Diem Stefan, Markert Eva, Jochum Wolfram, Kerl Katrin, French Lars E, Speiser Daniel E, Früh Martin, Flatz Lukas
Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
Klopp-Schulze L, Jörger M, Wicha S, Parra-Guillen Z, Kloft C. Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer . Int J Clin Pharmacol Ther 2016
Sep 19, 2016Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
Sep 19, 2016Int J Clin Pharmacol Ther 2016
Klopp-Schulze Lena, Jörger Markus, Wicha Sebastian G, Parra-Guillen Zinnia P, Kloft Charlotte
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Maury S, Braun T, Marolleau J, Cahn J, Chalandon Y, Lhéritier V, Beldjord K, Béné M, Ifrah N, Dombret H, Pignon J, Vey N, Hess U, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med 2016; 375:1044-53.
Sep 15, 2016Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Sep 15, 2016N Engl J Med 2016; 375:1044-53
Maury Sébastien, Braun Thorsten, Marolleau Jean-Pierre, Cahn Jean-Yves, Chalandon Yves, Lhéritier Véronique, Beldjord Kheira, Béné Marie C, Ifrah Norbert, Dombret Hervé, Pignon Jean-Michel, Vey Norbert, Hess Urs, Chevret Sylvie, Thomas Xavier, Heim Dominik, Leguay Thibaut, Huguet Françoise, Chevallier Patrice, Hunault Mathilde, Boissel Nicolas, Escoffre-Barbe Martine
Neuronal ganglia as a cause of peripheral nerve lesion
Leupold D, Schilg-Hafer L, Felbecker A, Tettenborn B, Hundsberger T (2016). Neuronal ganglia as a cause of peripheral nerve lesion.
Sep 13, 2016Neuronal ganglia as a cause of peripheral nerve lesion
Sep 13, 2016SFCNS
Leupold Daniela, Schilg-Hafer Lenka, Felbecker Ansgar, Tettenborn Barbara, Hundsberger Thomas
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
Kreissl S, Borchmann P, Engert A, Diehl V, Fuchs M, Flechtner H, Rueffer J, Shonukan O, Soekler M, Hitz F, Halbsguth T, Behringer K, Brillant C, Mayer A, Goergen H, Mueller H. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol 2016; 17:1453-1462.
Sep 6, 2016Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group
Sep 6, 2016Lancet Oncol 2016; 17:1453-1462
Kreissl Stefanie, Borchmann Peter, Engert Andreas, Diehl Volker, Fuchs Michael, Flechtner Hans-Henning, Rueffer Jens Ulrich, Shonukan Oluwatoyin, Soekler Martin, Hitz Felicitas, Halbsguth Teresa Veronika, Behringer Karolin, Brillant Corinne, Mayer Axel, Goergen Helen, Mueller Horst
appendix 8: Prostate cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Genitourinary-Cancers)
Parker C, Gillessen Sommer S, Horwich A. appendix 8: Prostate cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Genitourinary-Cancers). Ann Oncol 2016; 27:v146-v147.
Sep 1, 2016appendix 8: Prostate cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Genitourinary-Cancers)
Sep 1, 2016Ann Oncol 2016; 27:v146-v147
Parker C, Gillessen Sommer Silke, Horwich A
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC cancer 2016; 16:656.
Aug 19, 2016Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
Aug 19, 2016BMC cancer 2016; 16:656
Bickel Angelika, Koneth Irene, Enzler-Tschudy Annette, Neuweiler Jörg, Flatz Lukas, Früh Martin
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer H, Kosiorek H, Dueck A, Scherber R, Slot S, Zweegman S, Te Boekhorst P, Senyak Z, Schouten H, Sackmann F, Fuentes A, Hernández-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Paoli C, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian J, Zhang P, Gale R, Mesa R. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica 2016; 102:85-93.
Aug 18, 2016Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Aug 18, 2016Haematologica 2016; 102:85-93
Geyer Holly L, Kosiorek Heidi, Dueck Amylou C, Scherber Robyn, Slot Stefanie, Zweegman Sonja, Te Boekhorst Peter Aw, Senyak Zhenya, Schouten Harry, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Döhner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N, Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L, Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M, Paoli Chiara, Passamonti Francesco, Andreasson Bjorn, Ferrari Maria L, Rambaldi Alessandro, Samuelsson Jan, Cannon Keith, Birgegard Gunnar, Xiao Zhijian, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Kiladjian Jean-Jacques, Zhang Peihong, Gale Robert Peter, Mesa Ruben A
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Jörger M, Behringer D, Ko Y, Hilger R, Roessler M, Kloft C, Henrich A, Moritz B, Miller M, Salamone S, Kopp H, Mayer F, von Pawel J, Kraff S, Fischer J, Eberhardt W, Gauler T, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27:1895-902.
Aug 8, 2016Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Aug 8, 2016Ann Oncol 2016; 27:1895-902
Jörger Markus, Behringer D M, Ko Y-D, Hilger R A, Roessler M, Kloft C, Henrich A, Moritz B, Miller M C, Salamone S J, Kopp H-G, Mayer F, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms
Rothermundt C, Sternberg C, Schmidinger M, Rini B, Porta C, Oldenburg J, McDermott D, Larkin J, Grünwald V, Escudier B, Eisen T, von Rappard J, Putora P. Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World J Urol 2016
Aug 3, 2016Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms
Aug 3, 2016World J Urol 2016
Rothermundt Christian, Sternberg C N, Schmidinger M, Rini B, Porta C, Oldenburg J, McDermott D, Larkin J, Grünwald V, Escudier B, Eisen T, von Rappard J, Putora Paul Martin
Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes
Xin B, Groll M, Driessen C, van der Stelt M, Kisselev A, van der Marel G, Filippov D, Florea B, Besse A, Huber E, de Bruin G, Overkleeft H. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. J Med Chem 2016; 59:7177-87.
Aug 1, 2016Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes
Aug 1, 2016J Med Chem 2016; 59:7177-87
Xin Bo-Tao, Groll Michael, Driessen Christoph, van der Stelt Mario, Kisselev Alexei F, van der Marel Gijsbert A, Filippov Dmitri V, Florea Bogdan I, Besse Andrej, Huber Eva M, de Bruin Gerjan, Overkleeft Herman S
Anaplastische Gliome und ältere Glioblastompatienten
Hundsberger T (2016). Anaplastische Gliome und ältere Glioblastompatienten - Verbesserte Überlebenszeit durch Therapieintensivierung.
Aug 1, 2016Anaplastische Gliome und ältere Glioblastompatienten
Aug 1, 2016ASCO annual meeting 2016
Hundsberger Thomas